SiRNA-mediated integrin-linked kinase suppression: Nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing

Oligonucleotides

Volumn 19, Issue 2, 2009, Pages 129-140

  Verreault, Maite ^a,b   Bally, Marcel B ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATIONIC LIPOSOME; INTEGRIN LINKED KINASE; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; ELECTROPORATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE DELIVERY SYSTEM; GLIOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE SILENCING; HUMANS; LIPOSOMES; NEOPLASMS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING;

EID: 66249119716     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2008.0157     Document Type: Article

References (46)

1. CAVENEE, W.K. (1992). Accumulation of genetic defects during astrocytoma progression. Cancer. 70, 1788-1793.
2. CHEN, W.W., CHAN, D.C., DONALD, C., LILLY, M.B., and KRAFT, A.S. (2005). Pim family kinases enhance tumor growth of prostate cancer cells. Mol. Cancer Res. 3, 443-451.
3. CHONN, A., CULLIS, P.R., and DEVINE, D.V. (1991). The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146, 4234-4241.
4. DASS, C.R. (2002). Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy. Int. J. Pharm. 241, 1-25.
5. DELCOMMENNE, M., TAN, C., GRAY, V., RUE, L., WOODGETT, J., and DEDHAR, S. (1998). Phosphoinositide-3-OH kinasedependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. USA 95, 11211-11216.
6. DUNNE, J., DRESCHER, B., RIEHLE, H., HADWIGER, P., YOUNG, B.D., KRAUTER, J., and HEIDENREICH, O. (2003). The apparent uptake of fluorescently labeled siRNAs by electroporated cells depends on the fluorochrome. Oligonucleotides. 13, 375-380.
7. EDWARDS, L.A., THIESSEN, B., DRAGOWSKA, W.H., DAYNARD, T., BALLY, M.B., and DEDHAR, S. (2005). Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene. 24, 3596-3605.
8. EDWARDS, L.A., VERREAULT, M., THIESSEN, B., DRAGOWSKA, W.H., HU, Y., YEUNG, J.H., DEDHAR, S., and BALLY, M.B. (2006). Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol. Cancer Ther. 5, 645-654.
9. ELIYAHU, H., SERVEL, N., DOMB, A.J., and BARENHOLZ, Y. (2002). Lipoplex-induced hemagglutination: potential involvement in intravenous gene delivery. Gene Ther. 9, 850-858.
10. FILION, M.C., and PHILLIPS, N.C. (1997). Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta. 1329, 345-356.
11. FREIMARK, B.D., BLEZINGER, H.P., FLORACK, V.J., NORDSTROM, J.L., LONG, S.D., DESHPANDE, D.S., NOCHUMSON, S., and PETRAK, K.L. (1998). Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J. Immunol. 160, 4580-4586.
12. FRIEND, D.S., PAPAHADJOPOULOS, D., and DEBS, R.J. (1996). Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim. Biophys. Acta. 1278, 41-50.
13. FURNARI, F.B., HUANG, H.J., and CAVENEE, W.K. (1995). Genetics and malignant progression of human brain tumours. Cancer Surv. 25, 233-275.
14. HAAS-KOGAN, D., SHALEV, N., WONG, M., MILLS, G., YOUNT, G., and STOKOE, D. (1998). Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 8, 1195-1198.
15. HAGEMANN, C., MEYER, C., STOJIC, J., EICKER, S., GERNGRAS, S., KUHNEL, S., ROOSEN, K., and VINCE, G.H. (2006). High efficiency transfection of glioma cell lines and primary cells for overexpression and RNAi experiments. J. Neurosci. Methods. 156, 194-202.
16. HAY, N., and SONENBERG, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.
17. HEIDENREICH, O., KRAUTER, J., RIEHLE, H., HADWIGER, P., JOHN, M., HEIL, G., VORNLOCHER, H.P., and NORDHEIM, A. (2003). AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood. 101, 3157-3163.
18. HEYES, J., PALMER, L., BREMNER, K., and MACLACHLAN, I. (2005). Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. Journal of Controlled Release. 107, 276-287.
19. HOLLAND, E.C., CELESTINO, J., DAI, C., SCHAEFER, L., SAWAYA, R.E., and FULLER, G.N. (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25, 55-57.
20. KHAN, A., BENBOUBETRA, M., SAYYED, P.Z., NG, K.W., FOX, S., BECK, G., BENTER, I.F., and AKHTAR, S. (2004). Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J. Drug Target. 12, 393-404.
21. KOUL, D., SHEN, R., BERGH, S., LU, Y., DE GROOT, J.F., LIU, T.J., MILLS, G.B., and YUNG, W.K. (2005). Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol. Cancer Ther. 4, 1681-1688.
22. KUCAB, J.E., LEE, C., CHEN, C.S., ZHU, J., GILKS, C.B., CHEANG, M., HUNTSMAN, D., YORIDA, E., EMERMAN, J., POLLAK, M., and DUNN, S.E. (2005). Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 7, R796-807.
23. LAPPALAINEN, K., JAASKELAINEN, I., SYRJANEN, K., URTTI, A., and SYRJANEN, S. (1994). Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm. Res. 11, 1127-1131.
24. LV, H., ZHANG, S., WANG, B., CUI, S., and YAN, J. (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114, 100-109.
25. MCDONALD, P.C., OLOUMI, A., MILLS, J., DOBREVA, I., MAIDAN, M., GRAY, V., WEDERELL, E.D., BALLY, M.B., FOSTER, L.J., and DEDHAR, S. (2008). Rictor and Integrin-Linked Kinase Interact and Regulate AKT Phosphorylation and Cancer Cell Survival. Cancer Res. 68, 1618-1624.
26. OMIDI, Y., BARAR, J., and AKHTAR, S. (2005). Toxicogenomics of cationic lipid-based vectors for gene therapy: Impact of microarray technology. Curr. Drug Deliv. 2, 429-441.
27. PANZNER, E.A., and JANSONS, V.K. (1979). Control of in vitro cytotoxicity of positively charged liposomes. J. Cancer Res. Clin. Oncol. 95, 29-37.
28. PARDRIDGE, W.M. (2004). Intravenous, non-viral RNAi gene therapy of brain cancer. Expert. Opin. Biol. Ther. 4, 1103-1113.
29. ROTHMANN-COSIC, K., WESSENDORF, H., HELFRICH, J., THIEL, C., RIEMEN, G., BROSTERHUS, H., ET AL (2002). Buffer solution for electroporation and a method comprising the use of the same. European Patent Office, Patent # 1390518.
30. SARBASSOV, D.D., ALI, S.M., KIM, D.H., GUERTIN, D.A., LATEK, R.R., ERDJUMENT-BROMAGE, H., TEMPST, P., and SABATINI, D.M. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302.
31. SARBASSOV, D.D., GUERTIN, D.A., ALI, S.M., and SABATINI, D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307, 1098-1101.
32. SCHEID, M.P., MARIGNANI, P.A., and WOODGETT, J.R. (2002). Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol. Cell. Biol. 22, 6247-6260.
33. SHTILBANS, V., WU, M., and BURSTEIN, D.E. (2008). Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann. Diagn. Pathol. 12, 153-160.
34. SHUEY, D.J., MCCALLUS, D.E., and GIORDANO, T. (2002). RNAi: gene-silencing in therapeutic intervention. Drug Discov. Today. 7, 1040-1046.
35. SIMOES, S., FILIPE, A., FANECA, H., MANO, M., PENACHO, N., DUZGUNES, N., and DE LIMA, M.P. (2005). Cationic liposomes for gene delivery. Expert Opin. Drug Deliv. 2, 237-254.
36. SIOUD, M. (2005). On the delivery of small interfering RNAs into mammalian cells. Expert Opin. Drug Deliv. 2, 639-651.
37. SZULC, Z.M., BIELAWSKI, J., GRACZ, H., GUSTILO, M. MAYROO, N., HANNUN, Y.A., OBEID, L.M., and BIELAWSKA, A. (2006). Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg. Med. Chem. 14, 7083-7104.
38. TAN, C., CRUET-HENNEQUART, S., TROUSSARD, A., FAZLI, L., COSTELLO, P., SUTTON, K., WHEELER, J., GLEAVE, M., SANGHERA, J., and DEDHAR, S. (2004). Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell. 5, 79-90.
39. TANIGUCHI, K., YAMAMOTO, Y., ITAKURA, K., MIICHI, H., and HAYASHI, S. (1988). Assessment of ocular irritability of liposome preparations. J. Pharmacobiodyn. 11, 607-611.
40. TROUSSARD, A.A., MAWJI, N.M., ONG, C., MUI, A., ST-ARNAUD, R., and DEDHAR, S. (2003). Conditional knock-out of integrinlinked kinase demonstrates an essential role in protein kinase B/ Akt activation. J. Biol. Chem. 278, 22374-22378.
41. TROUSSARD, A.A., MCDONALD, P.C., WEDERELL, E.D., MAWJI, N.M., FILIPENKO, N.R., GELMON, K.A., KUCAB, J.E., DUNN, S.E., EMERMAN, J.T., BALLY, M.B., and DEDHAR, S. (2006). Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66, 393-403.
42. VERREAULT, M., WEBB, M.S., RAMSAY, E.C., and BALLY, M.B. (2006). Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr. Gene Ther. 6, 505-533.
43. WEBB, M.S., JOHNSTONE, S., MORRIS, T.J., KENNEDY, A., GALLAGHER, R., HARASYM, N., HARASYM, T., SHEW, C.R., TARDI, P., DRAGOWSKA, W.H., MAYER, L.D., and BALLY, M.B. (2007). In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phos-phatidylserine. Eur. J. Pharm. Biopharm. 65, 289-299.
44. YAN, W., CHEN, W., and HUANG, L. (2007). Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol. 44, 3672-3681.
45. YAU, C.Y., WHEELER, J.J., SUTTON, K.L., and HEDLEY, D.W. (2005). Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res. 65, 1497-1504.
46. ZABNER, J., FASBENDER, A.J., MONINGER, T., POELLINGER, K.A., and WELSH, M.J. (1995). Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. 270, 18997-19007.